pharmaphorum
AUGUST 10, 2021
Europe market has proved so hostile to gene therapies when it comes to pricing and reimbursement for gene therapies that bluebird bio has decided to quit the market altogether, according to Andrew Obenshain, president of its severe genetic diseases unit. market and will wind down in Europe.
Roots Analysis
FEBRUARY 21, 2022
Since the introduction of a gene sequencing method by Frederick Sanger in 1977, the field of genomic data collection and analysis has evolved significantly. Advancement in DNA sequencing technologies have resulted in noteworthy developments in various healthcare-related research fields, such as diagnostics and personalized medicine.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Discovery World
AUGUST 5, 2022
Three key members of the team – Dr Raquel Sanches-Kuiper, Vice President of Technology, Dr Matthew Hayes, Chief Technology Officer and John Edgell, Head of Cloud Engineering – explain how the company is doing this and what it means for the advancement of DNA synthesis in the lab. Why enzymatic synthesis? “We
pharmaphorum
OCTOBER 1, 2021
Shares in DNA sequencing specialist Oxford Nanopore rocketed after the company made its debut on the London Stock Exchange yesterday, rising nearly 50% to propel its valuation up towards the £5 billion ($6.7 The post Oxford Nanopore makes stellar debut on UK stock market appeared first on. billion) mark.
Roots Analysis
FEBRUARY 23, 2022
Presently, a variety NGS kits, including sample extraction kit, library preparation kit, amplification kit, purification kit and quantification kit, are available in the market. Next Generation Sequencing (NGS) Library Preparation Kits. NGS Library Preparation Kits Market. Players Engaged in the Domain. Web: [link].
Roots Analysis
OCTOBER 16, 2023
DNA cloning refers to the process of generating multiple copies of a particular DNA segment. DNA and Gene Cloning involves the isolation of a DNA sequence of any species ( often a gene ) and its insertion into a vector to enable growth without any alteration in the original DNA sequence.
pharmaphorum
AUGUST 21, 2020
Cambridge, UK-based Biofidelity has raised $12 million in first-round funding for its cancer diagnosis platform, which can detect mutations quicker than current approaches like gene sequencing. Both previously worked at Cambridge-based DNA sequencing specialist Base4 Innovation, where the technology was developed.
Expert insights. Personalized for you.
135 
Let's personalize your content